Brought to you by the team behind BioPharma-Reporter.com
What kind of consistency can industry expect from the FDA post pandemic?
How the US Food and Drug Administration (FDA) exercises flexibility has been an important and emerging issue for the past several years.
Chicago emerging as a life science and biopharma hub
Many turn to Boston and North Carolina’s Research Triangle to set up life science companies, but Chicago is now also fast becoming a draw in this respect. The city is emerging as a life science and biopharma hub and seems poised for even further growth, in CGT in particular.
Will Biden backed bills boost biosimilars uptake in the US?
Today we are launching a new series called The BioPharma Pod. Kicking off these broadcasts is the hot topic of biosimilars.
Bioproduction bottlenecks increasing due to staff shortages, says report
A shortage in expertise is causing bottlenecks in the biomanufacturing space with around half of drugmakers struggling to fill processing positions, an industry report finds.
'The sexiness of the ADC world' - CMOs talk antibody-drug hybrids at CPhI
Piramal’s COO Vijay Shah described antibody-drug conjugates (ADCs) as “a concept whose time has come” at the CPhI annual report press conference and recent investors in the technology echo his words.
Better single-use cross flow techs still needed says GE Healthcare
The biopharmaceutical manufacturing sector needs better cross flow filtration technologies according to GE Healthcare, which says that advances in bioreactor systems have not been matched downstream.